



1AP3 Rec'd PCT/PTO 06 MAR 2006  
PCT 1614

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/552,595  
Applicant: Morand *et al.*  
Filed: October 7, 2005  
TC/A.AU.: 1614  
Examiner: Unassigned

Confirmation No.: 2505

Docket No.: 11982.105003 BDW004 US  
Customer No.: 20786  
Title: Novel Methods for the Treatment of Inflammatory Diseases

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Sir:

The citation of information on the accompanying Form PTO/SB/08A, "Information Disclosure Statement by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A list of each cited reference is enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Applicant does not believe that any fees are due because this paper is being submitted before the mailing of a first Office Action on the merits, as under 37 C.F.R. § 1.97(b)(3). However, should the Commissioner determine that fees are due, he is hereby authorized to charge such fees and to credit any overpayment to Deposit Account No. 11-0980.


Respectfully submitted,

  
Madeline I. Johnston, Esq.  
Reg. No. 36,174


Dated: March 2, 2006  
King & Spalding LLP  
191 Peachtree Street, 45<sup>th</sup> Floor  
Atlanta, GA 30303-1763  
Office: (404) 572-4600/ Fax: (404) 572-5145

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on March 2, 2006.

  
Diane M. Guilfoyle

4010817\_1.DOC



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

**Complete if Known**

Application Number	10/552,595
Filing Date	October 7, 2005
First Named Inventor	Morand <i>et al.</i>
Group Art Unit	1614
Examiner	Unassigned
Attorney Docket Number	11982.105003 BDW004 US

4010836 1.DOC

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clms, Lns, Where Relevant Passages/Relevant Figs Appear
		Number	Kind Code (if known)			
	AA	4,616,025	A	Ezer <i>et al.</i>	10-07-1986	
	AB	6,235,910	B1	Beller <i>et al.</i>	05-22-2001	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
	AC	DE	19940211	A1	DeGussa-Hüls AG	03-23-2000		
	AD	GB	2,010,827	A	Eli Lilly & Co.	07-04-1979		

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**


Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 6
	AE	BACHER, M., <i>et al.</i> , "An essential regulatory role for macrophage migration inhibitory factor in T-cell activation," <i>Proc. Natl. Acad. Sci. USA</i> , 93(15):7849-7854 (July 23, 1996).	
	AF	BOZZA, M., <i>et al.</i> , "Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis," <i>J. Exp. Med.</i> , 189(2):341-346 (January 18, 1999).	
	AG	BUCALA, R., "MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response," <i>FASEB J.</i> , 10(14):1607-1613 (December 1996).	
	AH	CALANDRA, T., <i>et al.</i> , "MIF as a glucocorticoid-induced modulator of cytokine production," <i>Nature</i> , 377(6544):68-71 (September 7, 1995).	
	AI	DAVID, J.R., "Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction," <i>Proc. Natl. Acad. Sci. USA</i> , 56(1):72-77 (July 1966).	
	AJ	DONNELLY, S.C., <i>et al.</i> , "Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome," <i>Nat. Med.</i> , 3(3):320-323 (March 1997).	
	AK	JÜTTNER, S., <i>et al.</i> , "Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha," <i>J. Immunol.</i> , 161(5):2383-2390 (September 1, 1998).	
	AL	KARIMI, B., <i>et al.</i> , "Efficient and chemoselective conversion of carbonyl compounds to 1,3-dioxanes catalyzed with N-bromosuccinimide under almost neutral reaction conditions," <i>Org. Lett.</i> , 1(11):1737-1739 (1999).	
	AM	LACEY, D., <i>et al.</i> , "Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor," <i>Arthritis Rheum.</i> , 48(1):103-109 (January 2003).	

Examiner  
SignatureDate Con-  
sidered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Complete if Known</b>	
				Application Number	10/552,595
				Filing Date	October 7, 2005
				First Named Inventor	Morand <i>et al.</i>
				Group Art Unit	1614
				Examiner Name	Unassigned
Sheet	2	of	3	Attorney Docket Number	11982.105003 BDW004 US

4010836 1.DOC

<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	BA	LEECH, M., <i>et al.</i> , "Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of pro-inflammatory function and regulation by glucocorticoids," <i>Arthritis &amp; Rheumatism</i> , 42(8):1604-1608 (August 1999)	
	BB	LEECH, M., <i>et al.</i> , "Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant arthritis," <i>Arthritis &amp; Rheumatism</i> , 43(4):827-833 (April 2000).	
	BC	LEECH, M., <i>et al.</i> , "Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis," <i>Arthritis Rheum.</i> , 48(7):1881-1889 (July 2003)	
	BD	LIANG, X., <i>et al.</i> , "Solution-phase combinatorial synthesis using multicomponent Grignard reagents," <i>J. Chem. Soc., Perkin Trans. 1</i> , 2002:503-508 (2002)	
	BE	MIMURA, T., <i>et al.</i> , "Platelet anti-aggregant activity of 2,2-dimethylthiazolidine hydrochloride and 2-(4-hydroxy-3-methoxyphenyl)thiazolidine," <i>Chem. Pharm. Bull.</i> , 36(3):1110-1116 (1988).	
	BF	MITCHELL, R.A., <i>et al.</i> , "Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action," <i>J. Biol. Chem.</i> , 274(25):18100-18106 (June 18, 1999)	
	BG	MORAND, E.F., <i>et al.</i> , "Macrophage migration inhibitory factor: an emerging therapeutic target in rheumatoid arthritis," <i>Arthritis &amp; Rheumatism</i> , 48(2):291-299 (February 2003).	
	BH	PERRIN, C.L., <i>et al.</i> , "Stereochemical control in addition of nucleophiles to an amidinium ion," <i>J. Am. Chem. Soc.</i> , 123:4451-4458 (2001).	
	BI	QUALLICH, G.J., <i>et al.</i> , "Synthesis of 1,2,3,4-tetrahydroisoquinolines containing electron-withdrawing groups," <i>J. Org. Chem.</i> , 63(12):4116-4119 (1998).	
	BJ	ROBBE, Y., <i>et al.</i> , "Radioprotection chimique comparée de diverses structures hétérocycliques pentagonales à deux hétéroatomes," <i>Eur. J. Med. Chem. – Chim. Ther.</i> , 17(3):235-243 (1982).	
	BK	SABROE, I., <i>et al.</i> , "Asthma and MIF: innately Th1 and Th2," <i>Clin. Exp. Allergy</i> , 30(9):1194-1196 (September 2000).	
	BL	SAMAJDAR, S., <i>et al.</i> , "A new molecular iodine-catalyzed thioketalization of carbonyl compounds: selectivity and scope," <i>Tetrahedron Lett.</i> , 42:4425-4427 (2001).	
	BM	SAMPEY, A.V., <i>et al.</i> , "Annexin I and dexamethasone effects on phospholipase and cyclooxygenase activity in human synoviocytes," <i>Mediators Inflamm.</i> , 9(3-4):125-132 (2000).	
	BN	SAMPEY, A.V., <i>et al.</i> , "Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor," <i>Arthritis Rheum</i> , 44(6):1273-1280 (June 2001).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Complete if Known</b>	
				Application Number	10/552,595
				Filing Date	October 7, 2005
				First Named Inventor	Morand <i>et al.</i>
				Group Art Unit	1614
				Examiner Name	Unassigned
Sheet	3	of	3	Attorney Docket Number	11982.105003 BDW004 US

4010836 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	CA	SANTOS, L., <i>et al.</i> , "Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids," <i>Clin. Exp. Immunol.</i> , 123(2):309-314 (February 2001).	
	CB	SANTOS, L.L., <i>et al.</i> , "Suppression of adjuvant arthritis and synovial macrophage inducible nitric oxide by N-iminoethyl-L-ornithine, a nitric oxide synthase inhibitor," <i>Inflammation</i> , 21(3):299-311 (June 1997).	
	CC	SPYCHALA, J., "4-(Cyclic amidino)phenols- preparation and use in a diamidine synthesis," <i>Synthetic Communications</i> , 30(6):1083-1094 (2000).	
	CD	SRIKRISHNA, A., <i>et al.</i> , "A mild and simple procedure for the reductive cleavage of acetals and ketals," <i>Tetrahedron</i> , 31(11):3339-3344 (1995).	
	CE	SUMIYA, F., <i>et al.</i> , "Conjugated-triene intermediates in the Sommelet-Hauser rearrangement of cyclic 1-methyl-2-phenylammonium 1-methylides," <i>Chem. Pharm. Bull.</i> , 39(1):36-40 (January 1991).	
	CF	WEISER, W.Y., <i>et al.</i> , "Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor," <i>Proc. Natl. Acad. Sci. USA</i> , 86(19):7522-7526 (October 1989).	
	CG	WENIS, E., <i>et al.</i> , "The synthesis of p-aminosalicylic acid hydrochloride," <i>J. Am. Pharm. Assoc.</i> , 38:9-11 (1949) (Abstract only).	
	CH	WILK, I.J., <i>et al.</i> , "The action of lithium aluminum hydride on 3-methyl-5-phenylhydantoin and 5-phenylhydantoin," <i>J. Org. Chem.</i> , 15:1020-1022 (1950).	
	CI	YORDANOVA, K., <i>et al.</i> , "Eine neue Methode zur Darstellung von 2,4-disubstituierten Morpholinen," <i>Chem. Ber.</i> , 115(7):2635-1642 (1982).	
	CJ	YUS, M., <i>et al.</i> , "A new and direct synthesis of 2-substituted pyrrolidines," <i>J. Org. Chem.</i> , 66(18):6207-6208 (2001).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.